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Abstract 
Background: Methadone is commonly administered for chronic pain relief and treatment of opioid dependence. 
Concurrent with its increased consumption, toxicities and fatalities have increased. One of the adverse effects of opi-
oid analgesics, including methadone, is that of nephrotoxicity. Opioids can have an effect on renal function through 
several different mechanisms.
Methods: We searched common bibliographical databases for the terms methadone, toxicity, poisoning, kidney, 
renal, and nephrotoxicity and summarize our findings in this review.
Results: Methadone can have both direct and indirect effects on the kidney. These effects include rhabdomyolysis 
(leading to acute kidney injury), volumetric changes, renal lipidosis and amyloidosis, kidney growth during pregnancy, 
and kidney transplant rejection.
Conclusion: Improved understanding of the effects of methadone on kidney function can promote safer and more 
confident use of the drug.
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Background
Opioid dependence as a chronic condition is associated 
with morbidity and mortality (Bell et  al. 2009; Karrari 
et  al. 2013). In Iran there is a high prevalence of opioid 
abuse due to its geographic location in the Middle East 
and having a young population (Hassan Ziaaddini et  al. 
2011; Mehrpour and Sezavar 2012; Karrari et al. 2012).
Methadone is a synthetic mu-opioid receptor agonist 
widely used to treat opioid dependence (Alinejad et  al. 
2015; Grissinger 2011). It was first developed in Germany 
in 1937 and introduced to the US in 1947 by Eli Lilly and 
Company under the trade name of Dolophine (Lipman 
2008; Trafton and Ramani 2009). Since the mid-1960s, 
it has been used for the treatment of opioid dependence 
(Amiri-Aref et al. 2013; Nazari 2007). It is now on WHO 
(World Health Organization) list of essential medicines 
(Pilgrim et  al. 2013). More than 30,000 and 250,000 
patients have been treated in methadone maintenance 
programs in Australia and America, respectively (Pil-
grim et al. 2013; Thanavaro and Thanavaro 2011). In Iran, 
there are currently more than 1500 methadone centers 
(Aghabiklooei et al. 2014).
Methadone has pharmacokinetic and pharmacody-
namic properties that make it attractive for treating 
patients with opioid dependence (Fahey et al. 2003; Strain 
2002). Nevertheless, similar to other opioid medications, 
it has a potential for abuse and can either cause death 
directly or contribute to fatality indirectly (Amiri-Aref 
et  al. 2013; Van Den Broecke et  al. 2012). Methadone-
related reports of deaths have been accumulating over 
the past 40 years (Modesto-Lowe et al. 2010).
One of the potential adverse effects of opioid analge-
sics including methadone is nephrotoxicity (Atici et  al. 
2005; Lentine et al. 2015). Opioids influence renal func-
tion through various mechanisms and can cause or exac-
erbate a wide range of kidney diseases (Crowe et al. 2000; 
Mercadante and Arcuri 2004). The safe and effective 
administration of opioids can be an important concern 
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in patients with impaired renal function (Niscola et  al. 
2010).
The issue of patients’ individual responses to pain 
intensity, tolerance, and experience of adverse effects 
necessitates an understanding of the relationship 
between opioids and renal function (Melilli et  al. 2014; 
Mercadante and Arcuri 2004; Murtagh et  al. 2007). In 
this article we review methadone’s effects on the kidney.
Methods
A search was done on the terms methadone, toxicity, poi-
soning, kidney, renal, and nephrotoxicity in TUMS digi-
tal library, PubMed, Scopus, EmBase, and Google Scholar 
bibliographical databases. This review included the arti-
cles published between 2000 and 2015 though some very 
relevant articles published before 2000 were also taken 
into account. We excluded articles reporting animal stud-
ies and articles concerning the use of methadone in renal 
disease patients (Fig. 1).
This article is a literature review and does not con-
tain data from any intervention studies we performed. 
A formal consent was not required for this type of the 
study.
Methadone pharmacokinetics
Methadone’s chemical structure is different from that 
of a typical opioid by having the form of an open-chain 
amine. Having a strong affinity with a µ-opioid receptor, 
it is classified as a diphenyl-heptane derivative (Trescot 
et al. 2008).
Methadone has an oral bioavailability of 70 to 90% and 
reaches peak plasma concentrations within 2–4  h after 
being ingested, while its analgesic effect appears almost 
15  min after a subcutaneous injection. It has a long 
but variable plasma half-life of 15–55  h with a mean of 
approximately 24 h. Plasma protein binding in plasma is 
60–90%. Methadone is widely distributed among tissues, 
with an apparent volume of distribution (Vd) of 2–6 L/kg. 
It is metabolized in the liver, undergoing N-methylation 
and cyclization to be eliminated in an unconjugated form 
(Brown et al. 2004; Ferrari et al. 2004). Cytochrome P450 
(CYP) isozymes 3A4, 2D6, and to a lesser extent 1A2 are 
Ar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searching 
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Fig. 1 PRISMA 2009 flow diagram
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involved in metabolism. CYP3A4 enzyme activity may 
vary up to 30-fold between individuals. Moreover, a small 
percent of the population entirely lacks CYP2D6 enzyme 
(Gevirtz 2007; Kharasch et  al. 2004; Mehrpour 2013; 
Shinderman et al. 2003).
Up to 40% of a dose of methadone is eliminated by the 
kidney, depending on the urine pH. Renal drug clearance 
is significantly enhanced at a urine pH below 6 (Bernard 
et al. 2007).
Methadone is administered via oral, intravenous, rec-
tal, subcutaneous, sublingual, and intrathecal routes 
(Prommer 2010). In Iran and Australia, the main clinical 
replacement for opioid dependence is methadone syrup 
(Aghabiklooei et al. 2014; Pilgrim et al. 2013).
Low, intermediate, and high doses of methadone have 
been defined as doses <50, 50–100, and >100  mg/day, 
respectively. The dose for methadone maintenance varies 
between 30 and 125 mg/day (Strain 2002).
How methadone affects the kidney
Nephrotoxicity can occur as a direct or indirect result of 
exposure to drugs (Asangansi et  al. 2005; Ashley 2004; 
Dhodi et al. 2014; Kimmel et al. 2001; Orth 2002). Nearly 
20% of acute kidney injury (AKI) cases in the community 
are caused by drugs. Nephrotoxicity induced by drugs 
among older adults may reach as high as 66% (Bellomo 
2006; Kohli et al. 2000; Nash et al. 2002; Naughton 2008).
Addiction to opioids can lead to kidney injury in vari-
ous ways, such as acute glomerulonephritis caused by 
blood borne infection from contaminated needles and 
AKI caused by non-traumatic rhabdomyolysis (Darke 
et  al. 2006). AKI induced by methadone consumption 
usually results from rhabdomyolysis (Launay-Vacher 
et al. 2005).
Rhabdomyolysis and AKI (Table 1)
Rhabdomyolysis is a pathological and life-threatening 
disease caused by the release of toxic intracellular con-
stituents into the circulatory system following damage to 
the integrity of the cell membranes of skeletal muscles. 
Drugs, toxins, trauma, infections, ischemia, and meta-
bolic disorders are the main causes (Allison and Bedsole 
2003; Beetham 2000; Chatzizisis et  al. 2008; Gianno-
glou et al. 2007; Holt and Moore 2001; Melli et al. 2005; 
Moratalla et al. 2008; Tóth and Varga 2009; Warren et al. 
2002; Syed et  al. 2009). Most important non-traumatic 
causes include the use of illicit drugs, convulsive seizure, 
and excessive muscular strain (Welte et  al. 2004). It is 
estimated that exposure to toxic agents and medications 
are responsible for up to 80% of rhabdomyolysis cases in 
adults (Talaie et al. 2007). In 1971, Richter et al. described 
it to be caused by illicit drugs for the first time (Welte 
et al. 2004). Another study in 1985, described 3 patients 
who developed rhabdomyolysis following opiate toxicity 
(Blain et al. 1985). In two later studies, opiate toxicity was 
found to be the most common cause of rhabdomyolysis 
(Talaie et  al. 2007, 2008). In addition, rhabdomyolysis 
can be induced by methadone abuse (Criner et al. 2002; 
Iranmanesh 2015; Gramenz et al. 2010; Nanji and Doug-
las Filipenko 1983; Aghabiklooei et al. 2014; Eizadi-Mood 
et al. 2015).
Opioid intoxication leads to rhabdomyolysis through 
several mechanisms, such as producing prolonged 
immobility, direct toxic effects from narcotics, allergic 
reactions to narcotics, muscle tremor to spasm, and sus-
tained hypoxemia (Welte et al. 2004). The direct manner 
in which methadone may leads to rhabdomyolysis is by 
means of an increase in the muscular demand for oxy-
gen that augments muscle ischemia (Valga-Amado et al. 
2012). Other factors may cause rhabdomyolysis in metha-
done users: in a case reported by Gramenz et al. a patient 
injected 10 mg methadone tablets into the femoral artery, 
which caused limb ischemia without the presence of 
unconsciousness. The author stated that methadone tab-
lets contain microcrystals of cellulose, which had led to 
gangrene in the limb (Gramenz et al. 2010).
Rhabdomyolysis may present as asymptomatic eleva-
tion of the creatine phosphokinase (CK) serum level, or 
AKI with steadily rising serum creatinine concentrations 
(Lindner and Zierz 2003). Other common clinical mani-
festations include reddish brown urine due to myoglobi-
nuria, muscle weakness, fatigue, pain, and cramps (David 
2000; Guis et al. 2005).
The most worrisome complication of rhabdomyolysis 
is AKI (Deighan et  al. 2000; Valga-Amado et  al. 2012). 
Furthermore, in a study on 114 patients with acute poi-
soning and rhabdomyolysis, AKI was the main compli-
cation (Mousavi et  al. 2015). Baywaters and Beal first 
described rhabdomyolysis-induced AKI in 1941 (Chatz-
izisis et al. 2008). Up to 5–9% of all AKI cases are thought 
to be caused by rhabdomyolysis and 10–40% of patients 
with rhabdomyolysis have been reported to develop AKI 
(Vale 2007). AKI induced by rhabdomyolysis is mainly 
caused by disrupted muscle cells that release myoglobin. 
Renal vasoconstriction, ischaemia, formation of myoglo-
bin casts in the distal convoluted tubules, and myoglo-
bin’s direct cytotoxic effect on the epithelial cells of the 
proximal convoluted tubules are among the purported 
mechanisms of AKI. Myoglobin’s nephrotoxic action is 
intensified in the presence of an acidic urine pH caused 
by metabolic acidosis and hypovolemia (Richards 2000).
In most cases, rhabdomyolysis and AKI occur second-
ary to a preceding condition such as coma or prolonged 
immobilization (Corkery et al. 2004). Some examples of 
relevant studies are presented in Table 1 (Chakera 2008; 
Hojs and Sinkovič 1992; Hsu et  al. 2009; Mittal et  al. 
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2010; Schouwenberg and Deinum 2003; Valga-Amado 
et al. 2012; Weston et al. 1986).
A presumptive diagnosis of rhabdomyolysis is based 
on the detection of increases in the activity of creatine 
kinase (CK) (at least 5 times that of the normal level) in 
the plasma, or the presence of myoglobin in the urine 
(Vale 2007).
Reddish brown urine, muscular pain, and weakness 
are typical symptoms (Galley 2000; Warren et al. 2002). 
In 50% of patients, the central muscle groups like thighs 
and shoulders are mainly involved in pain; yet, no mus-
cular symptoms have been reported in over half of the 
cases. A major diagnostic element is urine reddish-brown 
color caused by myoglobinuria, which has been observed 
in almost half of the patients, but the diagnosis cannot 
be excluded in its absence. Clinical examinations have 
shown that the skin color changes in response to com-
pression necrosis and swollen and sensitive muscles may 
appear during palpation (Criddle 2003; Giannoglou et al. 
2007).
The diagnosis of rhabdomyolysis, especially during 
its early phase, might be difficult. Localization of the 
affected muscle and its differentiation from unaffected 
muscle groups may be accomplished through radiological 
techniques. Magnetic Resonance Imaging (MRI) is more 
sensitive than Computed Tomography (CT) or ultra-
sound techniques when detecting abnormal muscles. 
Signal intensities are increased and decreased on T2- and 
T1-weighted spin-echo images by the affected muscles, 
respectively. Moratalla et  al. (2008) reported a study on 
an unconscious 31-year old man after methadone con-
sumption. T2- and T1-weighted images of MRI scan had 
represented diffuse high and low signal intensities in the 
right upper extremity muscles, respectively, but the latter 
lacked any intramuscular hemorrhage signs (Moratalla 
et al. 2008).
Volumetric changes in the kidney
Opioids may decrease renal function by reducing glo-
merular filtration (GFR). Reduced systemic blood 
pressure caused by µ-opioids may cause increased anti-
diuretic hormone (ADH) secretion and increased central 
sympathetic outflow, leading to decreased renal perfu-
sion (Shahramian et al. 2009). Also, drugs such as metha-
done can cause pulmonary edema, and kidneys are very 
sensitive to hypoxia and respond to it via the infiltration 
of inflammatory cells (Shahramian et al. 2004, 2009). In 
an experimental study conducted by Shahramian et  al. 
(2009) on rats, a relative enhancement of kidney volume 
was found in the methadone group. In another study per-
formed by Jhaveri et al. an acute kidney injury and acid-
base disorder following a reduction of haemodynamics 
and volume depletion occurred after the consumption 
of 90  mg of methadone (Jhaveri and Webber 2008) 
(Table 1).
Renal lipidosis
Renal lipid storage is a phenomenon found in various dis-
eases, and may involve the glomerulus or tubules. Metha-
done intake and narcotic or intravenous (IV) drug abuse 
have been associated with this renal pathology. Porubsky 
et  al. described three patients enrolled in a methadone 
substitution program having renal lipidosis associated with 
a positive history of narcotic abuse. All three had proteinu-
ria and impaired renal function (Porubsky et al. 2014).
Renal amyloidosis
Secondary amyloidosis has been described as a cause of 
renal disease in chronic injection drug users (Buettner 
et al. 2014; Connolly et al. 2006; Crowe et al. 2000; Jung 
et  al. 2012). Repeated bacterial infections, especially 
those related to skin and soft tissues, have been associ-
ated with renal AA-amyloidosis caused by intravenous 
intake of methadone (Jung et  al. 2012; Miranda et  al. 
2007; Newey et al. 2007). Nephritic syndrome, proteinu-
ria, and even renal failure are responsible for the clinical 
manifestations of amyloidosis (Gillmore et al. 2001).
Kidney growth retardation
Methadone is often given to pregnant women who are 
in opioid-dependence treatment programs (Wright and 
Walker 2007). Perinatal methadone has an effect on the 
kidney as well as body and heart weights, suggesting a 
fairly generalized action of the drug on organ develop-
ment. Renal growth and noradrenergic development are 
affected by methadone (Grignolo et  al. 1982). A later 
study conducted by Ganapathy (2011) in humans sup-
ported the idea that the placenta and the developing fetus 
are influenced by the drugs. It was shown that drug abuse 
leads to the inhibition of serotonin, neurepinephrine, and 
dopamine, which, in turn, can enhance the levels of these 
monoamines within the placenta inter villous space. This 
would result in vasoconstriction, uterine contraction, 
compromised placental function, and growth retardation 
(Ganapathy 2011).
Kidney transplant rejection
Renal transplant is an important treatment for patients 
with end-stage renal disease (ESRD) (Monsalve et  al. 
2011). Adverse clinical outcomes may occur before the 
kidney transplant procedure in patients with a history of 
chronic opioid use including methadone (Barrantes et al. 
2013).
Lentine et al. conducted a study on 9047 selected kid-
ney recipients with 7  years of opioid use before trans-
plant procedure, who were normalized to morphine 
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equivalents such as methadone. The 3-year graft survival 
percentage was 84% in the recipients of liver with a his-
tory of narcotic use compared to 92% of those not having 
used narcotics. It was concluded that using high doses 
of opioid before kidney transplant increases the risks of 




Kidney damage can be minimized by early detection and 
treatment of rhabdomyolysis (Richards 2000). Treatment 
of the underlying cause of rhabdomyolysis and metabolic 
acidosis, prevention of AKI, early correction of electro-
lyte disorders, and management of other complications 
are the most important therapeutic interventions used 
in rhabdomyolysis (Chatzizisis et  al. 2008). Almost all 
patients suffering from rhabdomyolysis are hypovolemic, 
a factor that greatly predisposes them to renal failure 
because of reduced urine flow and aciduria (Curry et al. 
1989). Intravascular volume expansion can enhance renal 
blood flow, improve glomerular filtration, and increase 
urine flow, reducing the toxic effects of myoglobin on 
the tubules. Most clinicians administer intravenous NaCl 
0.9% (Holt and Moore 2001). A urinary catheter is rec-
ommended to be able to properly monitor hourly urinary 
output since treatment with a goal of 200–300  ml/h of 
urine excretion. Excessive administration of fluids can 
lead to non-cardiac pulmonary oedema, especially those 
with AKI (Esson and Schrier 2002). Urine alkalization 
may reduce myoglobin toxicity, and some clinicians use 
intravenous sodium bicarbonate (NaHCO3) administra-
tion (Warren et  al. 2002). Serum creatinine and blood 
urea levels should be frequently checked (Criner et  al. 
2002). Haemodialysis may be necessary in methadone-
induced rhabdomyolysis patients with worsening kidney 
function (Chaudhari et al. 2015).
Discussion
Renal failure is an important cause of mortality and 
morbidity related to methadone toxicity (Corkery et  al. 
2004; Aghabiklooei et  al. 2014), and rhabdomyolysis is 
responsible for most cases of AKI following methadone 
abuse. One of the debates on this topic is the unclear 
mechanism involved in methadone-induced rhabdo-
myolysis and AKI (Hojs and Sinkovič 1992). Methadone 
may induce rhabdomyolysis indirectly, for example as 
a result of coma leading to compression necrosis of a 
dependent extremity or respiratory depression causing 
hypoxemia. For instance, according to the studies con-
ducted by Mittal et  al. Hojs et  al. Hsu et  al. and Valga-
Amado et al. unconsciousness causes increased muscular 
demand for oxygen, as well as secondary ischemia, which 
may cause rhabdomyolysis (Hojs and Sinkovič 1992; 
Hsu et  al. 2009; Mittal et  al. 2010; Valga-Amado et  al. 
2012) (Table  1). Another explanation for an indirect 
Fig. 2 Management of rhabdomyolysis. Treatments of the main cause of rhabdomyolysis and metabolic acidosis, AKI prevention, early modification 
of electrolyte disorders, treatment, and management of other complications are the most important therapeutic interventions used in rhabdomy-
olysis
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cause of methadone-induced rhabdomyolysis is pulmo-
nary edema and resultant hypoxia, which also leads to 
increased muscular demand for oxygen. In the studies 
conducted by Tóth et al. and Hsu et al. hypoventilation is 
mentioned as one of the causes of rhabdomyolysis (Hsu 
et al. 2009; Tóth and Varga 2009) (Table 1). On the other 
hand, methadone may cause muscle injury as a result of 
direct toxicity. In a case reported by Gramenz et al. the 
patient presented with rhabdomyolysis after injection of 
10 mg methadone tablets into the femoral artery, which 
caused limb ischemia without the presence of uncon-
sciousness. The author stated that methadone tablets 
contain microcrystals of cellulose, which had led to gan-
grene in the limb (Gramenz et  al. 2010). Also the same 
conclusions were reported in the studies of Nanji and 
Douglas Filipenko (1983) and Fraser et al. (1971). These 
studies suggest that methadone itself could be a trigger 
for the induction of rhabdomyolysis.
Methadone toxicity outcomes can depend on us fac-
tors like age, gender, history of suicide attempts and 
psychological disorders, and the time interval between 
consumption of the drug and obtaining medical care 
(Eizadi-Mood et  al. 2015). All of the aforementioned 
cases, except Tóth and Varga (2009) involved young 
males; also, as described in the original articles, men 
more frequently present with acute methadone toxic-
ity. The proposed explanation for these findings is that 
men, especially while young, have a higher tendency to 
consume illicit drugs. It has been assumed that higher 
doses of methadone are more likely to be responsible for 
rhabdomyolysis and AKI. However, these consequences 
occur even at lower doses. Another assumption is that 
prolonged unconsciousness is a necessary risk factor for 
rhabdomyolysis. However, there are reports of patients 
who are awake yet suffer rhabdomyolysis (Nanji and 
Douglas Filipenko 1983). In such cases, there may be 
other factors, like the time interval between consumption 
of the drug and obtaining medical care that explain the 
outcome (ie, the patient may have had a prolonged epi-
sode of unconsciousness before waking up and present-
ing to medical care).
Limitation
In this review, most of the studies on methadone-induced 
rhabdomyolysis and AKI were case reports. Therefore, it 
is important to carry out more intervention and group 
studies to understand more about the causal factors and 
consequences of renal toxicity induced by methadone. 
Another limitation is that only a few reports and studies 
were found that addressed the direct effects of methadone 
in developing rhabdomyolysis and AKI. In addition, the 
direct effects of methadone on the kidneys, as opposed to 
rhabdomyolysis, were less frequently studied.
Conclusion
Apart from its efficacy in opioid dependence and chronic 
pain treatments, methadone can lead to renal toxicity. 
Therefore, it is crucial to gain knowledge concerning the 
relationship between renal function and opioids to avoid 
adverse outcomes. Also, it should be noted that many cases 
of death from methadone intoxication are preventable by 
the proper drug prescription, good monitoring, and atten-
tion to the signs and symptoms of toxicity. Thus, education 
and preventative approaches are essential for maintaining 
the health of addicted patients receiving methadone.
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